Goldman Sachs
WGBS

Goldman Sachs’s WaferGen Bio-systems, Inc. WGBS Stock Holding History

Goldman Sachs’s Portfolio WGBS Stock Details WGBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-4,029
Closed -$17K – 7256
2016
Q3 		$17K Buy
4,029
+578
+17% +$2.59K ﹤0.01% 6800
2016
Q2 		$14K Buy
3,451
+19
+0.6% +$71 ﹤0.01% 6809
2016
Q1 		$11K Sell
3,432
-904
-21% -$2.9K ﹤0.01% 6882
2015
Q4 		$16K Buy
+4,336
New +$21.5K ﹤0.01% 6899
2015
Q2 		– Sell
-2,836
Closed -$64K – 7581
2015
Q1 		$64K Sell
2,836
-4,578
-62% -$91K ﹤0.01% 6619
2014
Q4 		$111K Buy
+7,414
New +$138K ﹤0.01% 6535

Other funds holding WGBS

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Goldman Sachs's WGBS Position: Q4 2016 in Review

Goldman Sachs sold out of WaferGen Bio-systems, Inc. (WGBS) in Q4 2016, closing a stake of 4,029 shares — an estimated $17K sold.

Goldman Sachs first reported a position in WGBS in Q4 2014 and held it in 6 quarters. The position peaked at $111K in Q4 2014. 9 funds tracked by Wall St. Rank hold WGBS as of Q4 2016.

  • Goldman Sachs reported no remaining WaferGen Bio-systems, Inc. position as of Q4 2016 after selling out during the quarter.
  • Goldman Sachs sold 4,029 WaferGen Bio-systems, Inc. shares in Q4 2016, an estimated $17K.
  • Goldman Sachs first reported a position in WaferGen Bio-systems, Inc. in Q4 2014 and held it in 6 quarters.
  • Goldman Sachs's WaferGen Bio-systems, Inc. position peaked at $111K in Q4 2014.
  • 9 funds tracked by Wall St. Rank held WaferGen Bio-systems, Inc. as of Q4 2016.

Based on Goldman Sachs's 13F filing for Q4 2016, filed 14 Feb 2017.